Genitourinary
Prostate:
IRB #H-29292/RTOG #R0815: A Phase III Prospective Randomized Trial of Dose-Escalated Radiotherapy with or without Short-Term Androgen Deprivation Therapy for Patients with Intermediate-Risk Prostate Cancer
IRB #H-31383/RTOG #R0938: A Randomized Phase II Trial of Hypofractionated Radiotherapy for Favorable Risk Prostate Cancer
Prostate – High Risk:
CIRB #H-31595/RTOG #R0534: A Phase III Trial Of Short Term Androgen Deprivation With Pelvic Lymph Node Or Prostate Bed Only Radiotherapy (SPORT) In Prostate Cancer Patients with a Rising PSA after Radical Prostatectomy
IRB #H-29665: Phase II Study of Hypofractionated Stereotactic Body Radiation Therapy as a Boost To The Prostate for Treatment of Localized, Non-Metastatic, High Risk Prostate Cancer
Prostate – Metastatic:
IRB# pend/SWOG #1216: A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients With Newly Diagnosed Metastatic Hormone Sensitive Prostate Cancer (Not yet submitted to IRB)
WIRB #2012-1285/Oncogenex: (Affinity) A Randomized Phase 3 Study Comparing Cabazitaxel/Prednisone in Combination with Custirsen (OGX-011) to Cabazitaxel/Prednisone for Second-Line Chemotherapy in Men with Metastatic Castrate Resistant Prostate Cancer
Click here to view more information about this trial
WIRB #Pend Exelixis COMET: A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) vs. Prednisone in Metastatic Castration resistant Prostate Cancer Patients who have Received Prior Docetaxel and Prior Abiraterone or MDV3100 (pending site visit)
Renal:
IRB# H-31351/ SWOG #S0931 (EVEREST) : Everolimus for Renal Cancer Ensuing Surgical Therapy, A Phase III Study
Cancer Control:
IRB #H-31705/NCCTG #N08C9: Phase III, Randomized, Study of Sulfasalazine Versus Placebo in the Prevention of Acute Diarrhea in Patients Receiving Pelvic Radiation Therapy
